Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Neurotech International ( (AU:NTI) ) has shared an announcement.
Neurotech International has launched an Authorised Prescriber program for its NTI164 therapy, aimed at providing controlled access to patients with neurodevelopmental disorders in Australia. Managed by a leading paediatric neurologist, this program addresses the growing demand for NTI164 and generates real-world data to support future regulatory submissions and market positioning. The initiative is designed to be self-funding and aligns with upcoming policy changes, ensuring early market presence and aiding in regulatory and commercial decision-making.
More about Neurotech International
Neurotech International Limited is a clinical-stage biopharmaceutical development company focused predominantly on paediatric neurological disorders. The company is developing a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has conducted various clinical trials, including Phase II/III trials in Autism Spectrum Disorder (ASD) and other neurological conditions, demonstrating significant clinical benefits and safety.
Average Trading Volume: 999,890
Technical Sentiment Signal: Sell
Current Market Cap: A$16.79M
See more data about NTI stock on TipRanks’ Stock Analysis page.